ICER to probe for clinical justification of drug price hikes

The Institute for Clinical and Economic Review unveiled more details on its plans to evaluate whether price increases for "high-impact" drugs are justified

Read the full 232 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE